Motif Bio PLC Change of Adviser (5912O)
03 Ottobre 2019 - 8:00AM
UK Regulatory
TIDMMTFB
RNS Number : 5912O
Motif Bio PLC
03 October 2019
Motif Bio plc
("Motif Bio", or "the Company")
Change of Adviser
Motif Bio plc (AIM/NASDAQ: MTFB) is pleased to announce the
appointment of SP Angel Corporate Finance LLP as nominated adviser
and sole corporate broker with immediate effect.
AIM Rule 17 Disclosure
In accordance with AIM Rule 17 and Schedule Two (g)
sub-paragraph (v) of the AIM Rules for Companies (the "AIM Rules"),
the Company has been informed by Dr. Mary Lake Polan, Non-executive
Director, that NovaTract Surgical, Inc. a US company of which Dr.
Polan was a Director, entered into liquidation in 2015.
Update to disclosures required by Schedule 2(g) of the AIM
Rules
In addition to the directorships disclosed in the Company's
admission document dated 27 March 2015, directors of the Company
were, or had been in the past five years, at that time, directors
of the following companies:
Director Current Directorships Directorships held within
the past 5 years
Jonathan Subotnick House N/A
Gold
In addition to the past directorships disclosed in the
announcement of the appointment of Andrew Powell on 26 April 2019,
Andrew Powell had, at that time, been in the past five years a
director of the following companies:
Intermune UK Limited
Intermune UK & I Limited
Intermune Holdings Limited
Intermune Bristol Limited
Medivation Europe Limited
The person responsible for the release of this announcement on
behalf of Motif Bio plc is Jonathan Gold, Interim Chief Financial
Officer.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information, please contact:
Motif Bio plc ir@motifbio.com
Graham Lumsden (Chief Executive Officer)
SP Angel Corporate Finance LLP (NOMAD
& BROKER) +44 (0)20 3470 0470
David Hignell/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne (Sales
& Broking)
Walbrook PR Ltd. (UK FINANCIAL PR
& IR) +44 (0)20 7933 8780
Paul McManus/Lianne Cawthorne motifbio@walbrookpr.com
MC Services AG (EUROPEAN IR) +49 (0)89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu
Forward-Looking Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Motif Bio's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Motif Bio believes that these factors
include, but are not limited to, (i) Motif Bio's ability to obtain
shareholder approval in connection with the Proposed Restructuring,
(ii) Motif Bio's ability to execute the Proposed Capital Raise and
Proposed Restructuring (iii) the timing, progress and the results
of clinical trials for Motif Bio's product candidates, (iv) the
timing, scope or likelihood of regulatory filings and approvals for
Motif Bio's product candidates, (v) Motif Bio's ability to
successfully commercialise its product candidates, (vi) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (vii) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (viii) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (ix) the potential clinical utility and benefits of
Motif Bio's product candidates, (x) Motif Bio's ability to advance
its product candidates through various stages of development,
especially through pivotal safety and efficacy trials, (xi) Motif
Bio's estimates regarding the potential market opportunity for its
product candidates, (xii) Motif Bio's ability to raise additional
capital to sustain its operations and pursue its strategy and
(xiii) the factors discussed in the section entitled "Risk Factors"
in Motif Bio's Annual Report on Form 20-F filed with the SEC on
April 15, 2019, which is available on the SEC's web site,
www.sec.gov. Additionally, there can be no assurance that Motif Bio
will regain compliance with Nasdaq rules or maintain its ADS
listing on Nasdaq. Motif Bio undertakes no obligation to update or
revise any forward-looking statements
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPUURARKSARRUA
(END) Dow Jones Newswires
October 03, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024